



Official Licensing & Technical Publication
Portfolio for the SH-1 Molecule.

Publication: Bibebibebibe™ Magazine / Zenodo Data Registry


Core Assertion: A proprietary, high-affinity, non-steroidal androgen receptor (AR) antagonist engineered for purely localized, tissue-specific execution.



The Structural Failures of Legacy Protocols



Bypassing Systemic Boundaries via Targeted Architecture



Quantitative Pharmacological Baselines



K_i Affinity

Optimal binding constant ensuring localized competitive dominance over native DHT.




IC₅₀ Potency

Proven functional suppression in bioassays, immediately halting receptor activation.



Selectivity Index


>500-fold preference for AR domains, decisively suppressing secondary topical systemic risks.



Tissue Bioavailability

Deployed via a lipid delivery vector; reaches the dermal papilla matrix precisely within the targeted kinetic window.

The Safety Divide: Cosmetic Active vs. Investigational Risk



Total Operational Dominance

	Systemic Standard (Finasteride)	Topical Vasodilators (Minoxidil)	SH-1 Asset Architecture
Primary Mechanism	Systemic 5 α -Reductase Blockade	Non-Specific Vasodilation	Targeted Hydrophobic AR Antagonism
Endocrine Homeostasis	High Disruption (Serum Shift)	Unaffected	Complete Preservation (Local Action)
Receptor Displace Rate	Indirect/Non- Competitive	Zero Displacing Value	High Competitive Clearance
Follicular Micro-Repair	Negative/None	Marginal Maintenance	Active Reversal of Miniaturization

Strategic Licensing & Partnership Pathways

1

Scientific Validation

Zenodo Data Registry

Rigorous molecular validation & biomedical diagnostics.



2

Commercial Framework

Bibebibebibe™ Corporate Registry

Secure quantitative inputs & technical dossier clearings.



3

Market Deployment

International Development Partners

Pharmaceutical & premium dermatological commercialization.

For inquiries, technical dossier clearings, and secure data access, contact the office of Dr. Melvin Sewell: info@bibebibebibe.com.